H.C. Wainwright lowered the firm’s price target on Praxis Precision Medicines to $7 from $15 and keeps a Buy rating on the shares post the Q2 report. Data from pivotal studies are coming next year, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRAX:
- Praxis Precision Medicines reports Q2 EPS (49c), consensus (65c)
- Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Praxis Precision Medicines announces data from Essential1 study
- Praxis Precision Medicines announces results of EEG analysis of PRAX-628 study
- Praxis Precision Medicines Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study